This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.
BIIBNegative Net Change RHHBYNegative Net Change PRTANegative Net Change
biotechnology biotechs pharmaceuticals
Biotech's Blockbuster Week: 3 Stocks to Watch
by Andrew Rocco
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
IBBNegative Net Change CPRXPositive Net Change RXDXPositive Net Change XBINegative Net Change
biotechnology biotechs
Intercept (ICPT) Gains 12.4% in the Past Six Months: Here's Why
by Zacks Equity Research
Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.
ICPTPositive Net Change MDGLPositive Net Change CMMBNegative Net Change
biotechnology biotechs pharmaceuticals
DouYu International Holdings Limited Sponsored ADR (DOYU) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
DOYUNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Top Stocks Already up More Than 20% In 2023
by Derek Lewis
While inflation remains the market's primary concern, these three stocks have gotten off to a great start in 2023, already up more than 20% year-to-date. Can the strength continue? Their earnings outlooks suggest so.
JKSPositive Net Change AALPositive Net Change EXASPositive Net Change
airlines alt-energy biotechnology medical transportation
ETON Up as FDA Accepts NDA for Dehydrated Alcohol Injection
by Zacks Equity Research
Eton (ETON) gains as the its new drug application (NDA) for dehydrated alcohol injection for methanol poisoning is accepted for review by the FDA.
INONegative Net Change SNDXPositive Net Change ETONPositive Net Change
biotechnology biotechs pharmaceuticals
Should You Buy Charles River Laboratories (CRL) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
CRLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Mr Cooper (COOP)'s Technical Outlook is Bright
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
COOPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More
by Zacks Equity Research
Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.
REGNPositive Net Change AZNNegative Net Change MRNANegative Net Change EDITNegative Net Change
biotechnology biotechs pharmaceuticals
Should You Buy iQIYI, Inc. Sponsored ADR (IQ) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IQPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook
by Zacks Equity Research
bluebird bio, Inc. (BLUE) updates on the launch of gene therapy Zynteglo and provides cash burn guidance for 2023.
INONegative Net Change SNDXPositive Net Change
biotechnology biotechs pharmaceuticals
Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update
by Zacks Equity Research
Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs pharmaceuticals
Company News for Jan 10, 2023
by Zacks Equity Research
Companies In The News Are: REGN, LULU, DCT, BAX.
REGNPositive Net Change BAXPositive Net Change LULUNegative Net Change DCTNegative Net Change
biotechnology consumer-discretionary internet medical
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
by Zacks Equity Research
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
BMYPositive Net Change EXELNegative Net Change SNDXPositive Net Change IMCRNegative Net Change
biotechnology biotechs pharmaceuticals
FATE To End Janssen Deal and Prioritize Pipeline Development
by Zacks Equity Research
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
JNJPositive Net Change FATENegative Net Change SNDXPositive Net Change IMCRNegative Net Change
biotechnology biotechs pharmaceuticals
After Golden Cross, Ryanair (RYAAY)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
RYAAYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: GERN Surges on Study Data, PHAT, VERA Offer Updates & More
by Zacks Equity Research
Updates from Geron (GERN) and VERA are the key highlights from the biotech sector during the past week.
GERNNegative Net Change NVAXNegative Net Change PHATNegative Net Change CMMBNegative Net Change VERANegative Net Change
biotechnology pharmaceuticals
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
by Zacks Equity Research
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
SNDXPositive Net Change PHATNegative Net Change IMCRNegative Net Change
biotechnology biotechs pharmaceuticals
Gilead's (GILD) Application for Trodelvy Gets EMA Validation
by Zacks Equity Research
Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.
GILDPositive Net Change JNCEPositive Net Change ACLXNegative Net Change
biotechnology biotechs
Chemomab (CMMB) Mid-Stage Study for NASH Meets Primary Goal
by Zacks Equity Research
Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.
ICPTPositive Net Change VKTXNegative Net Change MDGLPositive Net Change CMMBNegative Net Change
biotechnology biotechs pharmaceuticals
After Golden Cross, KBC Group SA (KBCSY)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KBCSYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.
REGNPositive Net Change SNYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs pharmaceuticals
Best Momentum Stocks to Buy for December 30th
by Zacks Equity Research
IMCR, RGA and VCISY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2022.
RGAPositive Net Change VCISYNegative Net Change IMCRNegative Net Change
biotechnology finance
3 Hot Mid-Caps During a Cold December
by Derek Lewis
Despite the market's cold performance in December, these three stocks have remained hot, snapping the bearish trend. Their earnings outlooks suggest even more upside in 2023.
EXASPositive Net Change GDSNegative Net Change SMARPositive Net Change
biotechnology cloud-computing medical saas software
Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More
by Zacks Equity Research
Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.
LLYPositive Net Change GILDPositive Net Change PRQRPositive Net Change ACERNo Net Change KALAPositive Net Change
biotechnology biotechs